The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

被引：0
|
作者：
Binyu, W. [1 ]
Yao, F. [2 ]
Mengxia, C. [1 ]
Shan, P. [2 ]
Giancarlo, M. [3 ]
Junlong, Z. [1 ]
Shiwei, Z. [1 ]
Hongqian, G. [1 ]
Xuefeng, Q. [1 ]
机构：
[1] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Peoples R China
[3] San Giovanni Battista Hosp, Dept Urol, Turin, Italy
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0290
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 50 条
  • [1] The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy
    Wang, Binyu
    Fu, Yao
    Chen, Mengxia
    Peng, Shan
    Marra, Giancarlo
    Zhuang, Junlong
    Zhang, Shiwei
    Guo, Hongqian
    Qiu, Xuefeng
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (03) : 67.e9 - 67.e15
  • [2] Pathologic response to neoadjuvant therapy of high risk prostate cancer
    Berkut, M., V
    Artemjeva, A. S.
    Tolmachev, S. S.
    Reva, S. A.
    Petrov, S., V
    Nosov, A. K.
    ONKOUROLOGIYA, 2020, 16 (03): : 80 - 89
  • [3] Neoadjuvant Therapy in High-Risk Prostate Cancer
    Ashrafi, Akbar N.
    Yip, Wesley
    Aron, Monish
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (04) : 251 - 261
  • [4] AUO Neoadjuvant therapy for high-risk prostate cancer
    Rexer, H.
    Bogemann, M.
    Krafft, Ulrich
    UROLOGIE, 2024, 63 (11): : 1211 - 1212
  • [5] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [6] Presence of Hormone Resistant Intraductal Carcinoma of the Prostate after Neoadjuvant Hormone Therapy Is a Significant Prognostic Factor for High Risk Prostate Cancer in Radical Prostatectomy Patients
    Tsuzuki, Toyonori
    Kato, Masashi
    Kimura, Kyosuke
    Ishida, Ryo
    Sassa, Naoto
    Fukatsu, Akitoshi
    Hattori, Ryohei
    Gotoh, Momokazu
    MODERN PATHOLOGY, 2016, 29 : 268A - 268A
  • [7] Presence of Hormone Resistant Intraductal Carcinoma of the Prostate after Neoadjuvant Hormone Therapy Is a Significant Prognostic Factor for High Risk Prostate Cancer in Radical Prostatectomy Patients
    Tsuzuki, Toyonori
    Kato, Masashi
    Kimura, Kyosuke
    Ishida, Ryo
    Sassa, Naoto
    Fukatsu, Akitoshi
    Hattori, Ryohei
    Gotoh, Momokazu
    LABORATORY INVESTIGATION, 2016, 96 : 268A - 268A
  • [8] Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer
    Fan, Junjie
    Liang, Hua
    Gu, Yanan
    Jiang, Zhangdong
    Jiang, Fan
    Wang, Yingchun
    He, Dalin
    Wu, Kaijie
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 354e1 - 354e9
  • [9] A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
    Krafft, Ulrich
    Hadaschik, Boris A.
    Lueckerath, Katharina
    Herrmann, Ken
    EUROPEAN UROLOGY, 2024, 85 (03)
  • [10] Comparison of neoadjuvant vs concurrent/adjuvant androgen deprivation in men with high-risk prostate cancer receiving definitive radiation therapy
    Lee, Anna
    Becker, Daniel J.
    Lederman, Ariel J.
    Osborn, Virginia W.
    Shao, Meng S.
    Wong, Andrew T.
    Schwartz, David
    Schreiber, David
    TUMORI, 2017, 103 (04) : 387 - 393
12345